Septerna, Inc. (NASDAQ:SEPN) Given Average Rating of “Moderate Buy” by Brokerages

Septerna, Inc. (NASDAQ:SEPN) has received a consensus recommendation of “Moderate Buy” from the ten brokerages that are currently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, seven have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $43.1250.

Several equities analysts have recently commented on the company. Wall Street Zen lowered Septerna from a “buy” rating to a “hold” rating in a report on Saturday, March 14th. HC Wainwright reaffirmed a “buy” rating and set a $40.00 target price on shares of Septerna in a report on Wednesday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Septerna in a report on Tuesday, April 21st. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $60.00 target price on shares of Septerna in a report on Tuesday, March 10th. Finally, Wells Fargo & Company upped their target price on Septerna from $28.00 to $48.00 and gave the company an “overweight” rating in a report on Tuesday, March 3rd.

Septerna Stock Down 0.4%

Shares of NASDAQ SEPN opened at $24.75 on Thursday. The stock’s 50 day moving average price is $25.09 and its two-hundred day moving average price is $25.46. Septerna has a 52-week low of $8.51 and a 52-week high of $32.63. The stock has a market capitalization of $1.12 billion, a P/E ratio of -30.56 and a beta of 2.21.

Septerna (NASDAQ:SEPN) last announced its quarterly earnings data on Tuesday, May 12th. The company reported ($0.19) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.42) by $0.23. The firm had revenue of $26.52 million for the quarter, compared to analysts’ expectations of $16.98 million. Septerna had a negative return on equity of 12.72% and a negative net margin of 49.88%. On average, analysts anticipate that Septerna will post -1.87 EPS for the current year.

Insider Activity at Septerna

In other news, COO Elizabeth Bhatt sold 4,000 shares of the company’s stock in a transaction that occurred on Wednesday, April 15th. The stock was sold at an average price of $24.34, for a total transaction of $97,360.00. Following the completion of the transaction, the chief operating officer directly owned 174,209 shares of the company’s stock, valued at approximately $4,240,247.06. This represents a 2.24% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Samira Shaikhly sold 70,453 shares of the company’s stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $28.10, for a total value of $1,979,729.30. Following the transaction, the insider directly owned 793 shares of the company’s stock, valued at $22,283.30. This trade represents a 98.89% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 78,453 shares of company stock valued at $2,192,969 over the last ninety days. Corporate insiders own 4.30% of the company’s stock.

Hedge Funds Weigh In On Septerna

Hedge funds and other institutional investors have recently made changes to their positions in the business. Avoro Capital Advisors LLC boosted its position in shares of Septerna by 8.1% during the third quarter. Avoro Capital Advisors LLC now owns 1,337,500 shares of the company’s stock worth $25,158,000 after buying an additional 100,000 shares during the period. Covestor Ltd boosted its position in shares of Septerna by 55.8% during the third quarter. Covestor Ltd now owns 3,620 shares of the company’s stock worth $68,000 after buying an additional 1,296 shares during the period. Bank of New York Mellon Corp boosted its position in shares of Septerna by 6.1% during the first quarter. Bank of New York Mellon Corp now owns 58,709 shares of the company’s stock worth $1,411,000 after buying an additional 3,377 shares during the period. Y Intercept Hong Kong Ltd acquired a new position in shares of Septerna during the first quarter worth approximately $619,000. Finally, Strs Ohio boosted its position in shares of Septerna by 17.8% during the first quarter. Strs Ohio now owns 17,200 shares of the company’s stock worth $413,000 after buying an additional 2,600 shares during the period.

Septerna Company Profile

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body.